Chase Investment Counsel Corp Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Chase Investment Counsel Corp bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 54,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,126,000.

A number of other large investors also recently modified their holdings of the business. Rhumbline Advisers lifted its holdings in shares of Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock worth $6,518,000 after buying an additional 952 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 1,000 shares during the last quarter. KBC Group NV lifted its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,542 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 2.4% during the third quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company’s stock worth $1,436,000 after buying an additional 1,704 shares during the last quarter. Finally, Navellier & Associates Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 15.2% during the fourth quarter. Navellier & Associates Inc. now owns 14,163 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 1,869 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $22.89 on Friday. The business’s fifty day moving average price is $22.21 and its two-hundred day moving average price is $21.40. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $24.64. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of 19.40, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80.

Analyst Ratings Changes

A number of research analysts have recently commented on CPRX shares. Robert W. Baird began coverage on Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price target for the company. Bank of America restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, Truist Financial upped their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $32.00.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.